|
| Viral agent | Virus species | Modifications | Cancer type | Patient No. | Treatment regime | Status | References |
|
| MV-NIS | oncolytic measles virus—Edmonston vaccine strain | Transgene: thyroidal sodium iodide symporter | Recurrent or refractory multiple myeloma | Est 54 Enrolment closes June 2012 | Phase I trial Safe and dose escalation study of vaccine therapy when given with or without cyclophosphamide | Recruiting | http://www.clinicaltrials.gov/ Mayo Clinic NCT00450814 |
|
| JX-594 | Vaccinia—Wyeth | TK-ve Transgene inserted in TK region hGM-CSF (pE/L) and Lac-Z (p7.5) | Metastatic colorectal carcinoma | Est 20 Not open for enrolment yet | Neoadjuvant Phase 2a trial IV or IT injection followed by surgical resection of metastatic hepatic deposits | Not yet open | http://www.clinicaltrials.gov/ Jennerex Biotherapeutics, Inc. NCT01329809 |
|
| JX-594 | Vaccinia—Wyeth | TK-ve Transgene inserted in TK region hGM-CSF (pE/L) and Lac-Z (p7.5) | Metastatic colorectal carcinoma refractory to or intolerant of oxaliplatin, irinotecan, and Erbitux | Est 15 Enrolment closes June 2012 | Phase 1b dose escalation study IV injection biweekly (to evaluate the safety and tolerability of JX-594) | Results pending | http://www.clinicaltrials.gov/ Jennerex Biotherapeutics, Inc. NCT01380600 |
|
| Reolysin | Reovirus—type 3 Dearing | Wild-type | Metastatic or recurrent SCC of H&N | Est 280 enrolment closes Dec 2012 | Phase 3 IV administration in combination with paclitaxel and carboplatin versus chemotherapy treatment alone | Recruiting | http://www.clinicaltrials.gov/ Oncolytics Biotech NCT01166542 |
|
| Reolysin | Reovirus—type 3 Dearing | Wild-type | Recurrent or persistent ovarian, fallopian Tube, or primary peritoneal cancer | Est 110 enrolment closes December 2012 | Phase II weekly paclitaxel versus weekly paclitaxel with IV Reovirus | Recruiting | http://www.clinicaltrials.gov/ Gynecologic Oncology GroupNCT01199263 |
|
| Reolysin | Reovirus—type 3 Dearing | Wild-type | Recurrent or metastatic pancreatic cancer | Est 70 enrolment closes December 2013 | Phase II carboplatin, paclitaxel plus Reovirus versus carboplatin and paclitaxel | Recruiting | http://www.clinicaltrials.gov/ Arthur G. James Cancer Hospital & Richard J. Solove Research Institute NCT01280058 |
|
